These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

753 related items for PubMed ID: 17308267

  • 1. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL, Marchetti M, Barosi G.
    J Clin Oncol; 2007 Feb 20; 25(6):625-33. PubMed ID: 17308267
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
    Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM.
    J Clin Oncol; 2007 Feb 20; 25(6):634-41. PubMed ID: 17308268
    [Abstract] [Full Text] [Related]

  • 4. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
    Fagnani F, Colin X, Arveux P, Coudert B, Misset JL.
    Bull Cancer; 2007 Jul 20; 94(7):711-20. PubMed ID: 17723955
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
    Ward S, Pilgrim H, Hind D.
    Health Technol Assess; 2009 Jun 20; 13 Suppl 1():1-6. PubMed ID: 19567207
    [Abstract] [Full Text] [Related]

  • 7. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial.
    Purmonen TT, Pänkäläinen E, Turunen JH, Asseburg C, Martikainen JA.
    Acta Oncol; 2011 Apr 20; 50(3):344-52. PubMed ID: 21299447
    [Abstract] [Full Text] [Related]

  • 8. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU, Rezai M, Kümmel S, Kühn T, Warm M, Friedrichs K, Benkow A, Valentine WJ, Eiermann W.
    J Med Econ; 2013 Apr 20; 16(1):30-40. PubMed ID: 22966753
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE, Karnon J, Smith RE, Johnston SR, Brandman J, Sung JC, Gross PE.
    Am J Manag Care; 2006 Jul 20; 12(7):374-86. PubMed ID: 16834524
    [Abstract] [Full Text] [Related]

  • 11. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.
    Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC.
    J Clin Oncol; 2004 Mar 01; 22(5):854-63. PubMed ID: 14990641
    [Abstract] [Full Text] [Related]

  • 12. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
    Neyt M, Huybrechts M, Hulstaert F, Vrijens F, Ramaekers D.
    Health Policy; 2008 Aug 01; 87(2):146-59. PubMed ID: 18164510
    [Abstract] [Full Text] [Related]

  • 13. The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial.
    Skedgel C, Rayson D, Younis T.
    Value Health; 2009 Aug 01; 12(5):641-8. PubMed ID: 19490562
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP, Babigumira J, Tournier C, Goertz HP, Lubinga SJ, Perez EA.
    Value Health; 2019 Apr 01; 22(4):408-415. PubMed ID: 30975391
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.
    Blank PR, Schwenkglenks M, Moch H, Szucs TD.
    Breast Cancer Res Treat; 2010 Nov 01; 124(2):497-507. PubMed ID: 20364309
    [Abstract] [Full Text] [Related]

  • 20. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
    Garrison LP, Lalla D, Brammer M, Babigumira JB, Wang B, Perez EA.
    Cancer; 2013 Sep 01; 119(17):3113-22. PubMed ID: 23775560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.